MICHAEL L CAMILLERI

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Charlton 8 110, 200 First St SW, Rochester, MN 55905, USA
    IDrugs 13:921-8. 2010
  2. pmc Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome.
    Nelson Valentin
    Physiol Rep 5:. 2017
  3. pmc Novel Diet, Drugs, and Gastric Interventions for Gastroparesis
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota Electronic address
    Clin Gastroenterol Hepatol 14:1072-80. 2016
  4. pmc Exploring hypotheses and rationale for causes of infantile colic
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Neurogastroenterol Motil 29:. 2017
  5. ncbi Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches
    Michael Camilleri
    Department of Medicine, Pharmacology, and Physiology, Division of Gastroenterology, Mayo Clinic College of Medicine, Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, 200 First Street S W, Rochester, MN, 55905, USA
    Handb Exp Pharmacol . 2016
  6. pmc Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials
    Michael Camilleri
    C E N T E R, Mayo Clinic College of Medicine, Charlton 8 110, 200 First St S W, Rochester, MN, 55905, USA
    Dig Dis Sci 61:2357-72. 2016
  7. pmc Enhancing High Value Care in Gastroenterology Practice
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota Electronic address
    Clin Gastroenterol Hepatol 14:1376-84. 2016
  8. pmc Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Mayo Clinic, Rochester, Minnesota and
    Am J Physiol Gastrointest Liver Physiol 311:G365-76. 2016
  9. pmc Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Mayo Clinic, Rochester, Minnesota
    Am J Physiol Gastrointest Liver Physiol 311:G777-G784. 2016
  10. pmc Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota Electronic address
    Gastroenterology . 2016

Research Grants

Collaborators

Detail Information

Publications150 found, 100 shown here

  1. ncbi LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Charlton 8 110, 200 First St SW, Rochester, MN 55905, USA
    IDrugs 13:921-8. 2010
    ..LX-1031 was well tolerated in trials to date. In conclusion, LX-1031 appears promising for IBS-D. Optimal doses, efficacy in IBS clinical trials and safety need to be fully elucidated...
  2. pmc Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome.
    Nelson Valentin
    Physiol Rep 5:. 2017
    ..Further studies in patients with low-grade inflammation and intestinal barrier dysfunction at baseline are indicated...
  3. pmc Novel Diet, Drugs, and Gastric Interventions for Gastroparesis
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota Electronic address
    Clin Gastroenterol Hepatol 14:1072-80. 2016
    ..These promising approaches require formal, randomized, controlled trials and deployment in patients. The presence of concomitant antral hypomotility may be a significant factor in the responsiveness to interventions at the pylorus. ..
  4. pmc Exploring hypotheses and rationale for causes of infantile colic
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Neurogastroenterol Motil 29:. 2017
    ..Infantile colic is a frequent problem in neonates and infants. This review addresses current management including the results for nutrient modifications; soy-based formulas; and prebiotics, probiotics, and synbiotics...
  5. ncbi Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches
    Michael Camilleri
    Department of Medicine, Pharmacology, and Physiology, Division of Gastroenterology, Mayo Clinic College of Medicine, Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, 200 First Street S W, Rochester, MN, 55905, USA
    Handb Exp Pharmacol . 2016
    ....
  6. pmc Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials
    Michael Camilleri
    C E N T E R, Mayo Clinic College of Medicine, Charlton 8 110, 200 First St S W, Rochester, MN, 55905, USA
    Dig Dis Sci 61:2357-72. 2016
    ..The relative efficacy by gender has not been evaluated...
  7. pmc Enhancing High Value Care in Gastroenterology Practice
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota Electronic address
    Clin Gastroenterol Hepatol 14:1376-84. 2016
    ..The objective of this review is to identify common areas in gastroenterology practice where studies performed provide an opportunity for enhancing value or lowering costs...
  8. pmc Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Mayo Clinic, Rochester, Minnesota and
    Am J Physiol Gastrointest Liver Physiol 311:G365-76. 2016
    ..In conclusion, altered transcriptome (and to lesser extent protein) expression of ion transport, barrier, immune, and mast cell mechanisms in small bowel may reflect different alterations in function and deserves further study in IBS-D. ..
  9. pmc Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Mayo Clinic, Rochester, Minnesota
    Am J Physiol Gastrointest Liver Physiol 311:G777-G784. 2016
    ..However, it is still necessary to address the interaction between these factors in the gut and to appraise how they may influence hypervigilance in the central nervous system in patients with IBS...
  10. pmc Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota Electronic address
    Gastroenterology . 2016
    ..Finally, clinical evaluation and tests used in the assessment of patients presenting with chronic diarrhea are reviewed, and an algorithm guiding therapeutic decisions and pharmacotherapy is presented...
  11. doi Pharmacogenetics in irritable bowel syndrome
    Andrés Acosta
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, Division of Gastroenterology and Hepatology, Mayo Clinic, Charlton 8 110, 200 First St S W, Chester, MN 55905, Rochester, MN, USA 1 507 266 2305
    Expert Opin Drug Metab Toxicol 11:1187-91. 2015
    ..The objective of this editorial is to review the potential importance of pharmacogenetics in the treatment of IBS based on current evidence. ..
  12. pmc Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota Electronic address
    Clin Gastroenterol Hepatol 13:1051-7; quiz e61-2. 2015
    ..Understanding these mechanisms and developing clinical methods for their identification could improve management of patients with IBS-D. ..
  13. pmc Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials
    Nelson Valentin
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Mayo Clinic, 200 First St S W, Charlton Bldg, Rm 8 110, Rochester, MN 55905, USA 1 507 266 2305
    Expert Opin Investig Drugs 24:769-79. 2015
    ..New drugs are being developed for these disorders, targeting mechanisms involved in the pathophysiology of these diseases, specifically, motor function, intestinal secretion and bile acid modulation...
  14. pmc Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Mayo Clinic, Rochester, Minnesota
    Am J Physiol Gastrointest Liver Physiol 309:G10-20. 2015
    ..There are no differences in gene expression in IBS-D with high compared with normal fecal BA excretion...
  15. pmc Therapeutic targeting of bile acids
    Michael Camilleri
    Division of Gastroenterology and Hepatology, Department of Medicine, College of Medicine, Mayo Clinic, Rochester, Minnesota
    Am J Physiol Gastrointest Liver Physiol 309:G209-15. 2015
    ....
  16. pmc Peripheral mechanisms in appetite regulation
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic College of Medicine, Rochester, Minnesota Electronic address
    Gastroenterology 148:1219-33. 2015
    ..Understanding these mechanisms is key to the physiological control of feeding and the derangements that occur in obesity and their restoration with treatment (as shown by the effects of bariatric surgery). ..
  17. doi American college of gastroenterology monograph on the management of irritable bowel syndrome
    Michael Camilleri
    Mayo Clinic, Charlton 8 110, 200 First St S W Rochester, MN 55905, USA 1 507 266 2305
    Expert Opin Pharmacother 16:629-32. 2015
    ....
  18. pmc Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Mayo Clinic College of Medicine, Rochester, Minnesota
    Am J Physiol Gastrointest Liver Physiol 307:G508-16. 2014
    ..Genetic control of GPBAR1 receptor predisposing to pathobiological mechanisms in IBS provides evidence from humans in support of the importance of GPBAR1 to colonic motor and secretory functions demonstrated in animal studies. ..
  19. pmc Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    J Physiol 592:2967-80. 2014
    ..It is anticipated that identification of one or more disordered functions in clinical practice will usher in a renaissance in the management of IBS, leading to effective therapy tailored to the needs of the individual patient. ..
  20. ncbi Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy
    Michael Camilleri
    Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Gastroenterol 40:264-9. 2006
    ..Colonic transit was retarded in IBS patients treated with VSL#3 without induction of significant changes in bowel function. In summary, probiotics are promising therapies in IBS...
  21. pmc RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R and
    Am J Physiol Gastrointest Liver Physiol 306:G1089-98. 2014
    ..RNA-Seq and RT-PCR analysis of rectosigmoid mucosa in IBS-D show transcriptome changes that provide the rationale for validation studies to explore the role of mucosal factors in the pathobiology of IBS-D...
  22. ncbi Chronic diarrhea: a review on pathophysiology and management for the clinical gastroenterologist
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R Program, Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 2:198-206. 2004
  23. ncbi Pathophysiology as a basis for understanding symptom complexes and therapeutic targets
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 16:135-42. 2004
    ....
  24. doi Current medical treatments of dyspepsia and irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic College of Medicine, Charlton 8 110, 200 First Street Southwest, Rochester, MN 55905, USA
    Gastroenterol Clin North Am 39:481-93. 2010
    ..Novel approaches to treatment require approval, and promising agents are guanylate cyclase cagonists, atypical benzodiazepines, antibiotics, immune modulators, and probiotics...
  25. doi Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies
    M Camilleri
    Mayo Clinic, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 32:1113-23. 2010
    ..Prucalopride is approved in Europe for symptomatic treatment of chronic constipation in women with inadequate relief from laxatives...
  26. pmc Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 23:935-e398. 2011
    ..Our aim was to preliminarily assess association between 30 susceptibility loci for CD, three genes associated with PI-IBS, and PARM1, with colonic transit in lower functional gastrointestinal disorders (FGID)...
  27. pmc Is there a SERT-ain association with IBS?
    M Camilleri
    Center, Mayo Clinic, Charlton 8 110, 200 First St SW, Rochester, MN 55905, USA
    Gut 53:1396-9. 2004
  28. ncbi GIH clinical research 2003-2004: the year in review
    Michael Camilleri
    May Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 2:1043-7. 2004
    ..Clinical research advances will impact the management of digestive diseases...
  29. ncbi GIH clinical research update: 2004-2005
    Michael Camilleri
    Clinical Gastroenterology and Hepatology Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 3:1161-6. 2005
    ..These areas of clinical research demonstrate the breadth of significant advances that will impact on the clinical practice of gastroenterology and hepatology...
  30. ncbi New imaging in neurogastroenterology: an overview
    M Camilleri
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Neurogastroenterol Motil 18:805-12. 2006
    ....
  31. ncbi Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Group, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 19:77-84. 2007
    ..The evidence reviewed suggests that further studies are needed to explore the principles to prove or disprove the association...
  32. pmc Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 20:971-9. 2008
    ..The 1.0 mg dose was also efficacious in IBS-alternating. There were also weeks with significant reduction in bowel frequency and urgency. Asimadoline has been well tolerated in human trials to date...
  33. doi Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy
    Michael Camilleri
    Department of Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Gastroenterol 42:S123-5. 2008
    ..probiotics change bacterial flora? Do probiotics adhere to mucosa? What are the potential mechanisms of action of probiotics in IBS: immune function, motor, secretory, sensory, and fermentation? What is the efficacy of probiotics in IBS?..
  34. ncbi New therapeutic approaches in irritable bowel syndrome
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER Program, Mayo Clinic, Rochester, MN, USA
    Eur Rev Med Pharmacol Sci 12:139-40. 2008
  35. doi Mitochondrial DNA and gastrointestinal motor and sensory functions in health and functional gastrointestinal disorders
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Department of Health Sciences Research, College of Medicine, Mayo Clinic, Charlton 8 110, 200 First St S W, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 296:G510-6. 2009
    ..Thus variation in mtDNA may be associated with satiation, gastric emptying, and possibly pain; further studies of mtDNA in appetite regulation and larger numbers of patients with FGIDs are warranted...
  36. doi Lubiprostone for the treatment of opioid-induced bowel dysfunction
    Banny S Wong
    College of Medicine, Mayo Clinic, Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Rochester, MN 55905, USA
    Expert Opin Pharmacother 12:983-90. 2011
    ....
  37. pmc Brain-gut axis: from basic understanding to treatment of IBS and related disorders
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Pediatr Gastroenterol Nutr 54:446-53. 2012
    ..The criteria are similar in children and adults. The focus of the present review is the bowel dysfunction associated with IBS...
  38. doi Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome
    Michael Camilleri
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 303:G120-8. 2012
    ....
  39. pmc Genetics of human gastrointestinal sensation
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 25:458-66. 2013
    ..The objective was to review the genetics of human visceral pain with particular emphasis on pain associated with irritable bowel syndrome...
  40. pmc Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit
    Michael Camilleri
    Mayo Clinic, Charlton 8 110, 200 First St S W, Rochester, MN 55905
    Am J Physiol Gastrointest Liver Physiol 306:G13-26. 2014
    ..027) and rs1966265 with 24-h colonic transit (P = 0.066). Thus exome sequencing identified additional variants in KLB and FGFR4 associated with bile acids or colonic transit in IBS-D. ..
  41. pmc Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation
    Banny S Wong
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Mayo Clinic, Rochester, Minnesota, USA
    Clin Exp Gastroenterol 3:49-56. 2010
    ..Prucalopride is a well tolerated and efficacious prokinetic medication that should enhance the treatment of chronic constipation unresponsive to first-line treatments...
  42. pmc Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases
    Madhusudan Grover
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, College of Medicine, Mayo Clinic, 200 First St S W, Charlton 8 110, Rochester, MN 55905, USA
    J Gastroenterol 48:177-81. 2013
    ..Antidepressants appear to be more effective in the treatment of patients with anxiety or depression, but larger prospective trials assessing both clinical and pharmacodynamic effects on gut sensorimotor function are needed...
  43. pmc Guanylate cyclase C signaling: an intestinal secretory pathway where bugs, genes and new drugs intersect
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C, E, N, T, E, R, College of Medicine, Mayo Clinic, Charlton 8 110, 200 First Street SW, Rochester, MN 55905, USA
    Genome Med 4:50. 2012
    ..This newly identified gene in the etiology of a familial diarrhea provides a candidate target for the development not only of new treatments for diarrhea, but also of a new drug class to treat constipation...
  44. doi Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome
    Michael Camilleri
    Mayo Clinic, Clinical Enteric Neuroscience Translational and Epidemiological Research, Charlton 8 110, 200 First St S W, Rochester, 55905 MN, USA
    Expert Opin Pharmacother 14:1151-60. 2013
    ..The ultimate goal in this field is to identify the underlying cause of symptoms in order to individualize education of the patient, and to provide optimal treatment of this highly prevalent condition...
  45. pmc Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, Mayo Clinic, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 304:G553-60. 2013
    ....
  46. pmc Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 24:1076-e562. 2012
    ..Our aim was to assess inter- and intra-subject coefficients of variation (COV) of scintigraphic GE measurements in healthy subjects, and associations of GE with gender and body mass index (BMI)...
  47. pmc Clinical guideline: management of gastroparesis
    Michael Camilleri
    Department of Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Gastroenterol 108:18-37; quiz 38. 2013
    ..Partial gastrectomy and pyloroplasty should be used rarely, only in carefully selected patients. Attention should be given to the development of new effective therapies for symptomatic control...
  48. pmc Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics
    Andrea Shin
    1Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, College of Medicine, Mayo Clinic, Rochester, MN, USA
    Diabetes Care 36:41-8. 2013
    ..To investigate the pharmacokinetics (PK), pharmacodynamics, and safety of single-dose RM-131 in type 2 diabetic patients with gastrointestinal cardinal symptoms (GCSI) and previously documented delayed gastric emptying (DGE)...
  49. doi Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Charlton 8 110, 200 First St S W, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 303:G775-85. 2012
    ....
  50. pmc What are the important subsets of gastroparesis?
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 24:597-603. 2012
    ....
  51. pmc Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 302:G1075-84. 2012
    ..No published genome-wide association studies in functional gastrointestinal or motility disorders have been published...
  52. doi Governance of clinical research
    Michael Camilleri
    Division of Gastroenterology and Hepatology and Office of Human Research Protection, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 107:336-8. 2012
    ....
  53. pmc The role of pharmacogenetics in nonmalignant gastrointestinal diseases
    Michael Camilleri
    College of Medicine, Mayo Clinic, Charlton 8 110, 200 First Street South West, Rochester, MN 55905, USA
    Nat Rev Gastroenterol Hepatol 9:173-84. 2012
    ..However, pharmacogenetics could have a beneficial role in enabling pharmacotherapy for nonmalignant gastrointestinal diseases to be targeted to the individual patient...
  54. pmc New treatment options for chronic constipation: mechanisms, efficacy and safety
    Michael Camilleri
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Can J Gastroenterol 25:29B-35B. 2011
    ..Nevertheless, the spectrum of mechanisms and demonstrated efficacy and safety augur well for satisfactory treatment outcomes...
  55. ncbi Review article: clinical evidence to support current therapies of irritable bowel syndrome
    M Camilleri
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Aliment Pharmacol Ther 13:48-53. 1999
    ..In summary, current therapies targeted on the predominant symptoms in IBS are moderately successful. New therapies are needed to more effectively relieve this syndrome, not just symptoms...
  56. ncbi Clinical subgroups of chronic constipation: exploring the potential of polyethylene glycol
    M Camilleri
    Mayo Clinic, Rochester, MN, USA
    Ital J Gastroenterol Hepatol 31:S253-4. 1999
    ..However, first-line therapies such as dietary fibre and bulking agents should be tried initially prior to resorting to osmotic agents such as polyethylene glycol electrolyte solutions...
  57. ncbi Pharmacology and clinical experience with alosetron
    M Camilleri
    Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Expert Opin Investig Drugs 9:147-59. 2000
    ..It also improves quality of life, has a high degree of tolerability and has an excellent safety profile to date...
  58. ncbi Functional bowel disease: roles of sensation and motility
    M Camilleri
    Gastroenterology Research Unit, Mayo Clinic, Charlton 7 154 200 First St S W, Rochester, MN 55905, USA
    Schweiz Med Wochenschr 130:1772-81. 2000
    ..Serotonergic and adrenergic agents are among the novel approaches that may have a significant impact on these disorders...
  59. ncbi Review article: tegaserod
    M Camilleri
    Enteric Neuroscience Program, Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 15:277-89. 2001
    ..Tegaserod was well-tolerated; the most frequent adverse event was transient diarrhoea...
  60. ncbi Enteric nervous system disorders: genetic and molecular insights for the neurogastroenterologist
    M Camilleri
    Enteric Neuroscience Program, Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Neurogastroenterol Motil 13:277-95. 2001
    ....
  61. pmc Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls
    M Camilleri
    Enteric Neuroscience Program, Gastroenterology Research Unit, Mayo Clinic, Rochester, MN 55905, USA
    Gut 51:i34-40. 2002
    ..The principles and techniques involved in testing the hypothesis that visceral sensitivity is important are discussed, together with the controversies in the assumptions, methods, and interpretations of the data acquired to date...
  62. pmc Serotonergic modulation of visceral sensation: lower gut
    M Camilleri
    Enteric Neuroscience Program, Gastroenterology Research Unit, Mayo Clinic, Rochester, MN 55905, USA
    Gut 51:i81-6. 2002
    ..They offer promise for the development of novel therapies for the treatment and control of irritable bowel syndrome...
  63. ncbi Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 123:425-32. 2002
    ..Our hypothesis is that polymorphisms of the promoter region for the SERT influence colonic transit in response to treatment with alosetron in D-IBS...
  64. ncbi Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome
    M Camilleri
    Mayo Clinic, Rochesster, MN 55905, USA
    Aliment Pharmacol Ther 16:1407-30. 2002
    ..Patient and physician education, early identification of psychosocial issues and better therapies are important strategies to reduce the suffering and societal cost of irritable bowel syndrome...
  65. ncbi Drugs targeting functional bowel disorders: lessons from drug trials
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Curr Opin Pharmacol 2:684-90. 2002
    ....
  66. ncbi Diagnosis and treatment of enteric neuromuscular diseases
    Michael Camilleri
    Mayo Clinic, Charlton 8 110, 200 First St S W, Rochester, MN 55905, USA
    Clin Auton Res 13:10-5. 2003
    ....
  67. ncbi A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 1:111-21. 2003
    ....
  68. ncbi GI clinical research 2002-2003: the year in review
    Michael Camilleri
    Mayo Clinic, Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 1:415-20. 2003
  69. ncbi Objectives of the meeting: think opiates
    M Camilleri
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 16:1-2. 2004
  70. ncbi Effect of renzapride on transit in constipation-predominant irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R Program, Gastroenterology Research Unit, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 2:895-904. 2004
    ....
  71. ncbi Alvimopan, a selective peripherally acting mu-opioid antagonist
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Neurogastroenterol Motil 17:157-65. 2005
    ..This review addresses the basic and applied pharmacology and current evidence for the use of the medication, alvimopan, in clinical gastroenterology...
  72. ncbi Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Group, Mayo Clinic, Charlton 8 110, 200 First Street SW, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 290:G942-7. 2006
    ..Thus the ClC-2 activator lubiprostone accelerates small intestinal and colonic transit, which confers potential in the treatment of constipation...
  73. ncbi Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders
    Michael Camilleri
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 130:1421-34. 2006
    ..It is anticipated that the interaction between investigators of basic science, basic and applied pharmacology, and clinical trials will lead to better treatment of these disorders...
  74. pmc Does delayed gastric emptying really cause symptoms in functional dyspepsia?
    M Camilleri
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gut 55:909-10. 2006
  75. ncbi Management of patients with chronic abdominal pain in clinical practice
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 18:499-506. 2006
    ....
  76. ncbi Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans
    M Camilleri
    Department of Health Sciences Research, Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 19:30-8. 2007
    ..056) with the 10 and 20 mg t.i.d. doses. No safety issues were identified. ATI-7505 accelerates overall colonic transit and tends to accelerate GE and AC emptying and loosen stool consistency...
  77. pmc Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R Group and Gastroenterology Research Unit, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 132:17-25. 2007
    ..We explored the hypothesis that expression of these 2 proteins in colonic and rectal mucosa is abnormal in patients with IBS as compared with healthy controls...
  78. ncbi Is there a role for probiotics in irritable bowel syndrome?
    Michael Camilleri
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dig Liver Dis 38:S266-9. 2006
    ..These experimental and clinical observations suggest that probiotics may play a role in the management of IBS...
  79. ncbi Clinical practice. Diabetic gastroparesis
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiologic Research, Mayo Clinic College of Medicine, Rochester, MN, USA
    N Engl J Med 356:820-9. 2007
  80. ncbi Conflicts of interest and disclosures in publications
    Michael Camilleri
    Mayo Clinic, Charlton 8 110, 200 First Street SW, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 5:268-73. 2007
  81. ncbi Managing conflict of interest in clinical practice
    Michael Camilleri
    Conflict of Interest Review Board and Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 82:607-14. 2007
    ..Conflict of interest is of concern because it compromises the trust of the patient and of society in the individual physician or the medical center...
  82. ncbi Appetite and obesity: a gastroenterologist's perspective
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER Group, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 19:333-41. 2007
    ....
  83. ncbi Intestinal permeability and irritable bowel syndrome
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Group, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 19:545-52. 2007
    ....
  84. ncbi Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications
    M Camilleri
    CENTER Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 19:40-5. 2007
    ....
  85. pmc alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?
    Michael Camilleri
    Mayo Clinic, Charlton 8 110, 200 First St SW, Rochester, MN 55905, USA
    Gut 56:1337-8. 2007
  86. ncbi Functional dyspepsia: mechanisms of symptom generation and appropriate management of patients
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Group, Mayo Clinic College of Medicine, Charlton 8 110, 200 First Street, SW, Rochester, MN 55905, USA
    Gastroenterol Clin North Am 36:649-64, xi-x. 2007
    ..To achieve greater therapeutic efficacy, it may be necessary to target the therapeutic approach to a specific pathophysiology, such as impaired gastric emptying...
  87. ncbi Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation
    Michael Camilleri
    Mayo Clinic, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 294:G13-9. 2008
    ....
  88. doi Enteric neurodegeneration in ageing
    M Camilleri
    Departments of Medicine and Physiology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 20:185-96. 2008
    ..There is evidence that 5-HT(2) and 5-HT(4) mechanisms are involved in development, maintenance and survival of enteric neurons. Further research is needed to understand and potentially reverse enteric neurodegeneration...
  89. doi Enteric neurodegeneration in ageing
    M Camilleri
    Department of Medicine and Physiology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 20:418-29. 2008
    ..There is evidence that 5-HT(2) and 5-HT(4) mechanisms are involved in development, maintenance and survival of enteric neurons. Further research is needed to understand and potentially reverse enteric neurodegeneration...
  90. doi A placebo-controlled trial of prucalopride for severe chronic constipation
    Michael Camilleri
    College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 358:2344-54. 2008
    ..In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine4 receptor agonist, in patients with severe chronic constipation...
  91. pmc Candidate genes and sensory functions in health and irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Mayo Clinic, Charlton 8 110, 200 1st St SW, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 295:G219-25. 2008
    ....
  92. doi Intra-abdominal vagal blocking (VBLOC therapy): clinical results with a new implantable medical device
    M Camilleri
    The Mayo Clinic, Rochester, Minnesota, USA
    Surgery 143:723-31. 2008
    ..The aim is to assess the effects of vagal blocking on excess weight loss (EWL), safety, dietary intake, and vagal function...
  93. doi Drug development and IBS drugs: experience from the past, current challenges, and proposal for the future
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER Program, Mayo Clinic, Rochester, MN 55905, USA
    Curr Opin Pharmacol 8:671-6. 2008
    ..These extra validation steps will undoubtedly result in delays in drug development. Providing relief to patients should galvanize all parties to achieve effective and fair strategies for regulatory approval...
  94. pmc Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 135:1877-91. 2008
    ..The hope of providing relief to patients should galvanize all parties to achieve these goals...
  95. doi The stomach in diabetes: from villain to ally
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiologic Research CENTER, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 7:285-7. 2009
    ..The stomach is not always a villain, but is an ally in patients with type 2 diabetes...
  96. pmc Serotonin in the gastrointestinal tract
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Endocrinol Diabetes Obes 16:53-9. 2009
    ..To assess the role of serotonin and its control in the manifestations and treatment of lower functional gastrointestinal disorders...
  97. pmc Pharmacogenetics of low dose clonidine in irritable bowel syndrome
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 21:399-410. 2009
    ..alpha2A, GNbeta3 and SLC6A4 genotypes significantly modify responses to CLO on sensory and motor GI functions in health and IBS...
  98. pmc Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 21:734-e43. 2009
    ..This assay has potential as a non-invasive test for BAM in IBS...
  99. pmc Peripheral mechanisms in the control of appetite and related experimental therapies in obesity
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States
    Regul Pept 156:24-7. 2009
    ..Novel therapies are being developed to mimic or enhance these feedback mechanisms and to control appetite as a means to treat obesity...
  100. pmc Actions and therapeutic pathways of ghrelin for gastrointestinal disorders
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Nat Rev Gastroenterol Hepatol 6:343-52. 2009
    ..The potential of this new class of therapeutic agents to influence appetite and glycemic control strongly indicates that they should be tested in clinical trials...
  101. pmc Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Group, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 22:e15-26. 2010
    ..The 0-5 or 6 h 2-SE urine likely reflects both SI and colon permeability; the higher LMR in the 8-24 h urine relative to 0-2 h urine should be interpreted with caution and does not mean that colon is more permeable than SI...

Research Grants3

  1. ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS
    Michael Camilleri; Fiscal Year: 2007
    ..abstract_text> ..
  2. ALPHA 2 ADRENERGIC CONTROL IN IRRITABLE BOWEL SYNDROME
    Michael Camilleri; Fiscal Year: 2008
    ..Significance: This project will characterize pharmacogenetic mechanisms determining the response to clonidine through studies of candidate genes that control alpha2-adrenoreceptor function and norepinephrine transport in IBS. ..
  3. Cannabinoid Mechanisms in Human Gastrointestinal Motor and Sensory Functions
    MICHAEL L CAMILLERI; Fiscal Year: 2010
    ..These actions may be relevant to develop new treatments for IBS. The studies will also provide further understanding of the potential of medications like medical marijuana on stomach function that may be relevant to appetite control. ..